

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)



(10) International Publication Number
WO 2023/122600 A1

(51) International Patent Classification:

C07D 403/14 (2006.01) A61P 25/28 (2006.01)
A61K 31/496 (2006.01) A61P 35/00 (2006.01)
A61K 31/551 (2006.01) A61P 5/38 (2006.01)

(21) International Application Number:

PCT/US2022/082034

(22) International Filing Date:

20 December 2022 (20.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/292,104 21 December 2021 (21.12.2021) US
63/368,413 14 July 2022 (14.07.2022) US

(71) Applicant: **CORCEPT THERAPEUTICS INCORPORATED** [US/US]; 149 Commonwealth Drive, Menlo Park, California 94025 (US).

(72) Inventors: **MILLS, Mark**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **PHILLIPS, Andrew William**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **WASZKOWYCZ, Bohdan**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **HUNT, Hazel Joan**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **MORRISON, Angus**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **PUGLIESE, Angelo**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **GILLESPIE, Jonathan**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **FORDYCE, Euan**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US).

(74) Agent: **TRIMBLE, Alexander R.**; MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS

(57) Abstract: The present disclosure provides piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.

WO 2023/122600 A1